| Study | Reason for exclusion |
|---|---|
| Ajish 2014 | Not an RCT or quasi RCT. |
| Bonfig 2007 | Not an RCT or quasi RCT. |
| Charmandari 2001 | Not an RCT or quasi RCT. |
| ChiCTR‐TRC‐09000350 | Not relevant intervention. The effect of antisterone with angiotensin II and calcium ion antagonist in the treatment of hypertension with CAH. |
| Deuss 1985 | Not relevant intervention. The effect of a high and low dose of naloxone on ACTH was compared with placebo in people with Addison's disease, CAH, Cushing's disease and or Nelson's syndrome. |
| Johannsson 2009 | RCT, study of HC release in healthy volunteers, not people with CAH. |
| Kelch 1975 | Not relevant intervention. The aim was to investigate effects of glucocorticoid therapy, secretory patterns of HGH, FSH, LH and 17 OHP in people with CAH who were treated with or not treated with maintenance dose of HC. |
| Koenen 2009 | Not relevant intervention. The study assessed the effects of treatment with pioglitazone on insulin sensitivity and subcutaneous adipose tissue morphology and function in people with CAH who were insulin‐resistant. |
| Laue 1996 | Not relevant intervention. The pilot study to compare the effect of flutamide, testolactone, reduced‐dose HC and fludrocortisone versus hydrocortisone and fludrocortisone on normalizing linear growth, weight gain and bone maturation. |
| Mallappa 2015 | Not an RCT or quasi RCT. |
| Mathews 2004 | Not relevant intervention. A psychological study utilizing Edinburgh‐Crovitz Inventory and the performance of five tasks to measure hand preferences and, a dichotic listening task composed of consonant‐vowel nonsense syllables was a measure of language lateralization. |
| Merke 2000 | Not relevant intervention. Participants were treated with flutamide, testolactone, reduced does of HC and fludrocortisone. This regimen was compared to HC and fludrocortisone regimen. |
| Merza 2006 | Not an RCT. |
| NCT00001521 | Not relevant intervention. The study aims to determine if a combination of four drugs (flutamide, testolactone, reduced HC dose, and fludrocortisone) can normalize growth in children with CAH. |
| Neumann 2018 | Not an RCT |
| Panamonta 2003 | Not an RCT. |
| PRENATAL DEX | Not RCT. It is an evaluation of in utero dexamethasone on the cognitive development of children at risk of CAH. |
| Sarafoglou 2015 | Not relevant intervention. The study examined the absorption of an extemporaneously prepared HC suspension and compared it to tablets. |
| Spritzer 1990 | Not relevant intervention. Participants divided in 2 groups were treated with HC in order to suppress androgen secretion and cyproterone acetate antiandrogen therapy to inhibit peripheral androgen activity. |
| Turcu 2016 | Not relevant intervention. The study evaluates the safety and tolerability of the selective CRF1 receptor antagonist NBI‐77860 in women with classic 21‐hydroxylase deficiency and tested the hypothesis that CRF1 receptor blockade decreases early morning ACTH and 17 OHP in these people. |
| Verma 2010 | Not an RCT or quasi RCT. |
| Weise 2004 | Not relevant intervention. Participants were assigned to receive either an additional morning dose of HC or placebo, in addition to their usual glucocorticoid and mineralocorticoid replacement 1 hour before exercising. |
| Zhang 2011 | Not relevant intervention. Participants were randomised to different groups and received combinations of different antihypertensive medications at different doses. |
17 OHP: 17‐hydroxyprogesterone ACTH: adrenocorticotrpic hormone CAH: congenital adrenal hyperplasia CRF1: corticotropin‐releasing hormone receptor 1 HC: hydrocortisone RCT: randomised controlled trial